Durezol Emulsion
Product Images NDC 66758-086

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Durezol (NDC 66758-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5mlcarton (5mlcarton)

5mlcarton (5mlcarton)
Packaging label for DUREZOL (difluprednate ophthalmic emulsion) 0.05% sterile 5 mL bottle by Sandoz Inc. The label includes active ingredients, storage instructions, NDC 66758-086-75, manufacturer details, barcode, and warnings for ophthalmic use only and to keep out of reach of children.*
FDA Label Image

Difluprednate Structural Formula (Durezol 01)

Difluprednate Structural Formula (Durezol 01)
Chemical structure of difluprednate, the active ingredient in DUREZOL ophthalmic emulsion. The diagram displays the molecular arrangement including hydroxyl, ketone, and ester functional groups characteristic of this corticosteroid compound.*
FDA Label Image

Figure 1 Percent Of Subjects With Anterior Chamber Cells Clearing (cell Count = 0) (Durezol 02)

Figure 1 Percent Of Subjects With Anterior Chamber Cells Clearing (cell Count = 0) (Durezol 02)
A bar chart comparing the percent of subjects with anterior chamber cells clearing (cell count = 0) on Day 8 and Day 15 between Durezol QID (n=107) and placebo (n=220). The chart shows higher clearance percentages for Durezol at both time points (22% and 41%) compared to placebo (8% and 12%), with statistical significance indicated (P<0.05).*
FDA Label Image

Figure 2 Percent Of Subjects Who Were Pain Free (Durezol 03)

Figure 2 Percent Of Subjects Who Were Pain Free (Durezol 03)
A bar chart titled 'Percent of Subjects who were Pain Free' showing data for DUREZOL QID (n=107) and Placebo (n=220) on Days 3, 8, and 15. The chart compares percentages of pain-free subjects, with DUREZOL consistently higher at 45%, 58%, and 63% versus placebo at 25%, 27%, and 35%, respectively, with statistical significance indicated (P < 0.05).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.